



Investing to improve
the human condition.
Food and Health

Steve Rhodes
Chair and CEO

Todd Dollinger
Chair and CEO

Haim Brosh
CFO

November 2022



Legal disclaimer.

Important notice

This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. ("Company") or any of its portfolio companies nor shall it or any part of it form the basis of, or be relied on in connection with, any contract, commitment or any investment decision whatsoever in Singapore, Israel, the United States or in any other jurisdiction. The summary information herein does not purport to be complete. The information in this presentation should not be relied upon as any representation or warranty, express or implied, of the Company. No reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. The information is subject to change without notice.

The past performance of the Company is not necessarily indicative of its future performance. This presentation may contain statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the results of business operations and financial condition, industry, environment and future events and plans of the Company. Such forward-looking statements are not guarantees of future results, performance or achievements. Actual results, performance or achievements of the Company may differ from those expressed in the forward-looking statements as a result of various factors and assumptions, such as known and unknown risks and uncertainties, including those risk factors discussed in our Offer Document dated 16 November 2015 and in our other filings with the SGXNET. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. In light of these risks and uncertainties, actual events, results and developments could differ materially from those expressed or implied by the forward-looking statements. Reliance should not be placed on these forward-looking statements, which reflect the view of the Company or its officers as of the date of this presentation only. The Company does not undertake any obligation to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise.

None of the Company or any of its respective affiliates, advisers or representatives shall have any liability whatsoever for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation.

Neither this presentation nor any of its contents may be used without the prior written consent of the Company.

Agenda.

- 2022 selected portfolio achievements
- Overview of portfolio + guest presentation by Phytolon CEO
- H1 2022 financial sum-up
- Strategic focus for 2023
- Q&A

2022 achievements so far.

Selected raises


Completed to US\$19 million


Natural Food Colors

US\$14.65million


US\$1.6 million


US\$2.85 million

Strategic collaborations


Natural Food Colors


THE ORGANISM COMPANY


METOMOTION


VRIDDER

Regulatory clearance


escala medical

FDA clearance


LIMACA
MEDICAL

FDA
breakthrough
device
designation

Clinical & field trials


escala medical

 
liberDi METOMOTION


ceretrieve


Leviticus
Cardio


Pregnantech
Your Pregnancy. Our Focus.


NeuroQuest

A taste of our
portfolio.



The natural food color revolution.

A broad-spectrum of healthy plant-based colors produced via fermentation technology, using baker's yeast as a biofactory. Phytolon's high-quality and cost-effective pigments offer value for consumers, the environment and food industry.

Achievements:

- Full POC: color production & application in food products
- Commercial agreement with DSM
- Successful pilots with industry leaders including Nestlé
- R&D collaboration agreement with Ginkgo Bioworks

Financial stage:

- Last investment round: US\$14.5 million



Plant-based colors produced via cost-effective and sustainable fermentation of yeast

Founded 2018;
23 employees;
Yokne'am Illit, IL

Co-Founders:
Halim Jubran, PhD, CEO;
Tal Zeltzer, PhD, CTO

IP licensed from
Weizmann Institute of
Science

Funding US\$20.1 million

Investors (see below)





4 more agrifood frontrunners.

20 agrifood portfolio companies

FruitSpec.

Early-stage prediction of crop yields in orchards and vines

- Sales in the United States, South America, Israel and South Africa
- Strategic investors from China and South Africa




Technology platform for harvesting greenhouse tomatoes

- Partnership with Dutch horticulture technology supplier Ridder 
- First commercial sales in 2022
- Received investment from European Innovation Council



Artificial intelligence analytics employing drones for user-generated data acquisition for field crop management

- Strategic partners in Israel, North America, Latin America, Europe and Africa. 
- Acquired Terravion assets to bolster imagery capabilities.



Orally-administered disease prevention for shrimp and fish

- Strategic investors:



Needleless neurotoxin delivery for overactive bladder.

Ultrasound catheter used to deliver Xeomin® in the treatment of overactive bladder, a common bladder disorder.

Achievements:

- Successful first in human study
- Strategic collaboration agreement with Merz Therapeutics licensing Merz's botulinum neurotoxin A (Xeomin®) for needle-free use in urological procedures

Financial stage:

- Last investment round: US\$19 million



VENSCA

Ultrasound catheter delivers Xeomin® into the bladder wall painlessly and without needles.

-  **Founded** 2014
-  **CEO** Avner Geva
-  **IP Filed** PCT
-  **Funding Raised** US\$21 million
-  **Investors** Trendlines, IBF, Merz, Laborie, Lew Pell, Agriline



4 more leading healthcare companies.

35 healthcare portfolio companies



Meniscus repair system

- FDA and CE clearance
- Launched initial commercial sales in U.S., Latin America, U.K.
- Appointed leading surgeons to Scientific Advisory Board



Removable stent following sinus surgery

- Began sales in US
- FDA clearance



Digital home dialysis


- FDA clearance in process
- 2nd clinical trial underway
- Raised US\$8.1 million




Non-surgical, incision-free approach to treat pelvic organ prolapse

- FDA clearance
- 17 patient FIH clinical study with 1 year follow up completed – March 2022


Let's look at the
numbers.



Maturing portfolio, larger raises, higher values.



Book value vs. minimum exit value.



X4.4 is the weighted average increase in value of our ten exits, not including earnouts and royalties.

H1 2022: Financial Highlights.

	30 June 2022	31 December 2021
Portfolio value:	US\$81.0 million	US\$83.0 million
Book value:	US\$94.2 million	US\$102.5 million
NAV per share:	US\$0.12	US\$0.13
Net (loss)/profit	US\$ (11.9 million)	US\$4.1 million


Bronze award for Best Managed Board.



Trendlines was awarded the Bronze Award for Best Managed Board in the small-cap category of the Singapore Corporate Awards by the Business Times Singapore. The event recognizes exemplary corporate governance practices in Singapore's listed companies.



COP 27.



Nitza Kardish PhD. was invited to speak and moderate a panel at COP27 in Sharm el-Sheikh focusing on the intersection between agriculture and the climate crisis.

She presented alongside other dignitaries from Israel, namely the Director General and Chief Scientist of Israel's Ministry of Agriculture.

Strategic focus for 2023.

- Investment focus on current portfolio companies to maximize value
- Suspension of new company investment activity
- Reduction of 2023 operating expenses budget by US\$2 million vs 2021, net of consolidated portfolio company expenses and grants

Q&A.



Creating & developing companies
to improve the human condition.

SGX: 42T
OTCQX: TRNLY

+972.72.260.7000
www.trendlines.com



November 2022

Steve Rhodes, Chair and CEO
steve@trendlines.com

Todd Dollinger, Chair and CEO
todd@trendlines.com

Haim Brosh, CFO
haim@trendlines.com